Study of healthcare consumption of patients over 45 years with Chronic Obstructive Pulmonary Disease

Study identification

• EU PAS number:
  EUPAS5306
• Study ID:
  19572
• Official title and acronym:
  Study of healthcare consumption of patients over 45 years with Chronic Obstructive Pulmonary Disease
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  The Chronic Obstructive Pulmonary Disease (COPD) is defined as a chronic, slowly progressive disease, characterized by incompletely reversible reduction in airflow. It is very closely related to tobacco, responsible for the initiation and the perpetuation of the inflammatory mechanisms that cause bronchial and lung injuries. The symptoms (cough, sputum and dyspnea) induce an early limitation of physical activity, from daily life and work to sports and sleep.This disabling disease costs for society, in part due to the high frequency of comorbidities, including cardiovascular disease, diabetes, cancer, anxiety and psychiatric disorders.In clinical practice, COPD is under-diagnosed and under-treated with an under-use of spirometry to confirm the diagnosis.Based on the French national health insurance database (EGB) which contains healthcare reimbursement data of 1/97 of the French population, the objectives of this study is to define the support in 2006 and in 2011 of patients aged over 45 years with COPD (characteristics of patients, consumption, individual costs, factors associated with high costs and with repeated hospitalizations related to the disease). A longitudinal analysis studies also the support over the period of six years. Finally the healthcare consumption and cost is studied according to comorbidities (cardiovascular, psychiatric, diabetes).
• Study status:
  Finalised

Research institutions and networks

Institutions

Université Claude Bernard Lyon 1

Study timelines

Date when funding contract was signed

Actual:15/11/2011

Study start date

Actual:15/11/2011

Date of final study report

Actual:02/08/2013

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GSK

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable